23:24 , Apr 18, 2017 |  BC Extra  |  Company News

Alpine finds public path through Nivalis

Immunology company Alpine Immune Sciences Inc. (Seattle, Wash.) and cystic fibrosis play Nivalis Therapeutics Inc. (NASDAQ:NVLS) said they will merge in an all-stock transaction. Upon the deal's close, expected in 3Q17, the combined company will...
16:24 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Cavosonstat: Ph II SNO-7 data

Top-line data from the double-blind, U.S. Phase II SNO-7 trial in 19 adult CF patients who had 1 copy of the F508del mutation in the CF transmembrane conductance regulatory (CFTR) gene and a second mutation...
21:10 , Jan 27, 2017 |  BC Week In Review  |  Company News

Nivalis restructuring

Nivalis will reduce headcount by 25 (83%) to about 5 to preserve cash while exploring strategic alternatives, including an acquisiton and merger. The headcount reduction will include President and CEO Jon Congleton, CMO and EVP...
22:56 , Dec 14, 2016 |  BC Week In Review  |  Clinical News

Cavosonstat: Ph II data

Top-line data from a double-blind, U.S. Phase II trial in 138 CF patients with 2 copies of the F508del mutation in the CF transmembrane conductance regulatory (CFTR) gene showed that twice-daily 200 and 400 mg...
00:38 , Nov 22, 2016 |  BC Week In Review  |  Clinical News

Cavosonstat: Completed Ph II enrollment

Nivalis completed enrollment of 19 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 400 mg oral N91115 twice daily for 12 weeks plus Kalydeco ivacaftor. The trial enrolled adult CF patients with 1...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

Cavosonstat: Completed Phase II enrollment

Nivalis completed enrollment of 138 patients who have 2 copies of the F508del mutation in the CF transmembrane conductance regulatory ( CFTR ) gene in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 200 and...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

N91115: Phase II started

Nivalis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 400 mg oral N91115 twice daily for 12 weeks plus Kalydeco ivacaftor in about 20 patients. The trial is enrolling adult CF patients with...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Clinical News

N91115: Phase II ongoing

Nivalis said an IDMC recommended continuation of a double-blind, placebo-controlled, U.S. Phase II trial of oral N91115 based on interim safety data on the lower dose. The trial is evaluating 200 and 400 mg N91115...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

N91115: Phase II started

Nivalis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 200 and 400 mg oral N91115 twice daily with oral Orkambi lumacaftor/ivacaftor in 135 CF patients who have 2 copies of the F508del mutation...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Clinical News

N91115: Phase Ib data

Top-line data from a double-blind, U.S. Phase Ib trial in 51 CF patients with 2 copies of the delta F508 CF transmembrane conductance regulator ( CFTR ) mutation showed that twice-daily 50, 100 and 200...